Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results

Brodeur, 1993, Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment, J Clin Oncol, 8, 1466, 10.1200/JCO.1993.11.8.1466 Cohn, 2009, The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report, J Clin Oncol, 27, 289, 10.1200/JCO.2008.16.6785 Janoueix-Lerosey, 2009, Overall genomic pattern is a predictor of outcome in neuroblastoma, J Clin Oncol, 27, 1026, 10.1200/JCO.2008.16.0630 Schleiermacher, 2007, Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification, Br J Cancer, 97, 238, 10.1038/sj.bjc.6603820 Ambros, 2009, International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee, Br J Cancer, 100, 1471, 10.1038/sj.bjc.6605014 Schouten, 2002, Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification, Nucleic Acids Res, 30, e57, 10.1093/nar/gnf056 Ambros, 2011, A multilocus technique for risk evaluation of patients with neuroblastoma, Clin Cancer Res, 17, 792, 10.1158/1078-0432.CCR-10-0830 Combaret, 1989, Clinical value of N-myc oncogene amplification in 52 patients with neuroblastoma included in recent therapeutic protocols, Eur J Cancer Clin Oncol, 25, 1607, 10.1016/0277-5379(89)90305-2 van Dijk, 2005, Multiplex ligation-dependent probe amplification for the detection of chromosomal gains and losses in formalin-fixed tissue, Diagn Mol Pathol, 14, 9, 10.1097/01.pas.0000146701.98954.47 Villamón, 2008, Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma, Virchows Arch, 453, 47, 10.1007/s00428-008-0633-6